Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2020, with a specific reporting date of December 3, 2020. The document serves as a transaction notification regarding insider dealings by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's Sharesave Plan 2012.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of specific equity transactions.
| Instrument | Transaction Type | Price | Volume | Date |
|---|---|---|---|---|
| Ordinary Shares (25 pence each) | Grant of Options | £10.34 | 870 | 2020-11-27 |
| Ordinary Shares (25 pence each) | Grant of Options | £10.34 | 870 | 2020-11-27 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two identical option grants executed on November 27, 2020, on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine disclosure of executive compensation-related transactions.
Key Facts for Investor Verification
- Transaction Nature: Two separate grants of options over Ordinary Shares were made to senior executives.
- Executives Involved: Mr. J Ford (SVP & General Counsel) and Mr. N Hirons (SVP, Global Ethics & Compliance).
- Plan Details: Transactions were conducted under the Sharesave Plan 2012.
- Valuation: The option exercise price was set at £10.34 per share.
- Volume: Each executive received options covering 870 shares.